Entrada Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

TRDA$5.25+11.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Collaboration revenue	$1,614	$19,570	$24,122	$173,384
Operating expenses:
Research and development	38,361	31,257	108,312	91,900
General and administrative	10,304	9,971	31,500	28,606
Total operating expenses	48,665	41,228	139,812	120,506
(Loss) income from operations	(47,051)	(21,658)	(115,690)	52,878
Other income:
Interest and other income	3,571	5,766	11,936	14,346
Total other income	3,571	5,766	11,936	14,346
(Loss) income before provision for income taxes	(43,480)	(15,892)	(103,754)	67,224
Provision for (benefit from) income taxes	654	(1,860)	832	2,729
Net (loss) income	$(44,134)	$(14,032)	$(104,586)	$64,495
Net (loss) income per share, basic	$(1.06)	$(0.35)	$(2.53)	$1.79
Net (loss) income per share, diluted	$(1.06)	$(0.35)	$(2.53)	$1.72
Weighted‑average common shares outstanding, basic	41,462,567	40,629,602	41,293,108	36,118,930
Weighted‑average common shares outstanding, diluted	41,462,567	40,629,602	41,293,108	37,583,486
Other comprehensive income:
Unrealized gain on marketable securities	221	1,301	664	777
Total other comprehensive income	221	1,301	664	777
Total comprehensive (loss) income	$(43,913)	$(12,731)	$(103,922)	$65,272

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.